MO · Full Picture

ALTRIA GROUP, INC. — the full picture

Earnings window · 2026-05-27 to 2026-09-24 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Settlement and FDA Payments · UnclassifiedPriority 72
    -41.7% operating_income; 1 forward row(s); structured_verified
    Based on current agreements and estimates, the estimated amounts that Altria may charge to cost of sales for payments related to State Settlement Agreements and FDA user fees are $3.0 billion on average for the next three years.
  2. Operating Income and Margins · Operating income & profitabilityPriority 67
    +21.6% operating_income (realized); 2 sources (news, sec_filing); structured_verified
    Operating income increased $1,074 million (21.4%) for the six months ended June 30, 2026 versus the six months ended June 30, 2025 due primarily to higher OCI (which includes the impact of a non-cash impairment of the e-vapor reporting unit goodwill in 2025).
  3. Guidance / Outlook · Guidance & outlookPriority 64
    3 sources (news, press_release, sec_filing); 10 forward row(s); quote_verified
    Analysts predict Altria's earnings to reach $9.5 billion by April 2029, up from current $6.9 billion.
  4. Premium Cigarette Demand Pressure · Demand, orders & backlogPriority 63
    3 sources (news, press_release, sec_filing); quote_verified
    Engineers Gate Manager LP significantly reduced its stake in Altria Group by 60.9% in the second quarter.
  5. Revenue Performance and Mix · Revenue growth & mixPriority 58
    +4.6% revenue (realized); 3 sources (news, press_release, sec_filing); 2 forward row(s); structured_verified
    Altria reported Q1 EPS of $1.32 and revenue of $4.76 billion, a 5.3% year-over-year increase.
  6. Capital Expenditure Guidance · Capital expenditurePriority 56
    -1.1% cash; 3 sources (news, press_release, sec_filing); 4 forward row(s); quote_verified
    Capital expenditures for 2026 are expected to be in the range of $375 million to $450 million, up from the previous range of $300 million to $375 million, primarily driven by investments to support the USSTC Facilities Consolidation.
  7. Liquidity and Cash Position · Liquidity & cash positionPriority 53
    2 sources (news, press_release); quote_verified
    Altria reported cash and cash equivalents of $2,367 million as of June 30, 2026, down from $4,474 million as of December 31, 2025.
  8. Capital Return Program · Buybacks & dividendsPriority 52
    2 sources (news, press_release); 2 forward row(s); quote_verified
    As of June 30, 2026, Altria had $665 million remaining under its $2 billion share repurchase program, which expires on December 31, 2026.
  9. Liquidity and Debt Position · Debt, leverage & refinancingPriority 52
    +3.3% liability (realized); 2 sources (press_release, sec_filing); 1 forward row(s); structured_verified
    PM USA (Guarantor), a 100% owned subsidiary of Altria, fully and unconditionally guarantees as primary obligor the payment and performance of the Parent’s obligations under the guaranteed debt instruments, subject to release under customary circumstances.
  10. Litigation and Legal Risk · Litigation & settlementsPriority 50
    -1.6% operating_income (realized); 3 sources (news, press_release, sec_filing); 2 forward row(s); structured_verified
    Altria incurred total costs of $172 million primarily associated with the ITC exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE and patent infringement lawsuits related to the NJOY Transaction, which were offset by insurance recoveries of $71 million.
  11. Macroeconomic Consumer Pressure · Macroeconomic conditionsPriority 50
    2 sources (news, press_release); quote_verified
    Altria said macroeconomic uncertainty and inflation pressures led consumers to opt for lower-priced alternatives, contributing to declines in premium cigarette and nicotine-pouch demand.
  12. Oral Tobacco Margin Pressure · Gross marginPriority 48
    +0.1% assets; 2 sources (press_release, sec_filing); 2 forward row(s); quote_verified
    A hypothetical 1% increase in the discount rate used to estimate the fair value of the Skoal trademark would have resulted in an impairment charge of approximately $90 million based on the 2025 annual impairment test.

Threads by pillar

Revenue & Demand Priority 81 · 6 threads

Costs & Margins Priority 83 · 9 threads

Capital & Balance Sheet Priority 79 · 11 threads

Strategy & Portfolio Priority 41 · 2 threads

Legal, Regulatory & Policy Priority 65 · 6 threads

Guidance & Outlook Priority 64 · 1 thread

Macro & Market Conditions Priority 61 · 4 threads

Management & Governance Priority 28 · 1 thread

Unclassified Priority 85 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income-41.7%+41.7%+16.9%
assets+1.1%+1.3%—
cash-1.1%+1.1%-3.2%
margin——-2.0%
net_income——+18.4%
revenue——+5.6%
liability——+3.3%